

# Precision medicine based on epigenomics: the paradigm

Nature Reviews Clinical Oncology

14, 682-694

DOI: [10.1038/nrclinonc.2017.97](https://doi.org/10.1038/nrclinonc.2017.97)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Missing data in open-data era – a barrier to multiomics integration. <i>Bio-Algorithms and Med-Systems</i> , 2018, 14, .	1.0	0
2	Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. <i>EBioMedicine</i> , 2018, 30, 138-147.	2.7	116
3	Towards personalized computational oncology: from spatial models of tumour spheroids, to organoids, to tissues. <i>Journal of the Royal Society Interface</i> , 2018, 15, 20170703.	1.5	101
4	Methylated genomic loci encoding microRNA as a biomarker panel in tissue and saliva for head and neck squamous cell carcinoma. <i>Clinical Epigenetics</i> , 2018, 10, 43.	1.8	17
5	Mod Squad: Altered Histone Modifications in Cancer. , 2018, , 481-481.		0
6	A similar effect of P16 hydroxymethylation and true-methylation on the prediction of malignant transformation of oral epithelial dysplasia: observation from a prospective study. <i>BMC Cancer</i> , 2018, 18, 918.	1.1	6
7	CUP Syndrome. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2018, 115, 157-162.	0.6	25
8	Making the right calls in precision oncology. <i>Nature Biotechnology</i> , 2018, 36, 692-696.	9.4	8
9	Cancer of unknown primary – Epidemiological trends and relevance of comprehensive genomic profiling. <i>Cancer Medicine</i> , 2018, 7, 4814-4824.	1.3	44
10	Retinoic acid-induced 2 (RAI2) is a novel tumor suppressor, and promoter region methylation of RAI2 is a poor prognostic marker in colorectal cancer. <i>Clinical Epigenetics</i> , 2018, 10, 69.	1.8	21
11	Principles of DNA methylation and their implications for biology and medicine. <i>Lancet, The</i> , 2018, 392, 777-786.	6.3	436
12	&lt;p&gt;Precision oncology: lessons learned and challenges for the future&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 7525-7536.	0.9	10
13	Precision oncology in Latin America: current situation, challenges and perspectives. <i>Ecancermedalscience</i> , 2019, 13, 920.	0.6	11
14	Management options for pulmonary nodules with cancer of unknown primary. <i>Shanghai Chest</i> , 0, 3, 17-17.	0.3	0
15	Epigenetic heterogeneity in cancer. <i>Biomarker Research</i> , 2019, 7, 23.	2.8	145
16	Hierarchical Classification of Cancers of Unknown Primary Using Multi-Omics Data. <i>Cancer Informatics</i> , 2019, 18, 117693511987216.	0.9	13
17	DNA methylation and chromatin modifiers in colorectal cancer. <i>Molecular Aspects of Medicine</i> , 2019, 69, 73-92.	2.7	34
18	Development of a versatile DNMT and HDAC inhibitor C02S modulating multiple cancer hallmarks for breast cancer therapy. <i>Bioorganic Chemistry</i> , 2019, 87, 200-208.	2.0	37

#	ARTICLE	IF	CITATIONS
19	New and Emerging Biomarkers in Endocrine Pathology. <i>Advances in Anatomic Pathology</i> , 2019, 26, 198-209.	2.4	11
20	Combined Targeted Resequencing of Cytosine DNA Methylation and Mutations of DNA Repair Genes with Potential Use for Poly(ADP-Ribose) Polymerase 1 Inhibitor Sensitivity Testing. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 198-213.	1.2	2
21	Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the "U" out of "CUP". <i>British Journal of Cancer</i> , 2019, 120, 141-153.	2.9	71
22	Identification of a metastatic lung adenocarcinoma of the palate mucosa through genetic and histopathological analysis: a rare case report and literature review. <i>BMC Cancer</i> , 2019, 19, 52.	1.1	5
23	Engineering Precision Medicine. <i>Advanced Science</i> , 2019, 6, 1801039.	5.6	55
24	Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e32-e37.	0.9	18
25	CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence. <i>EBioMedicine</i> , 2020, 61, 103030.	2.7	67
26	Sentinel node theory helps tracking of primary lesions of cancers of unknown primary. <i>BMC Cancer</i> , 2020, 20, 639.	1.1	6
27	The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary. <i>Seminars in Diagnostic Pathology</i> , 2021, 38, 193-198.	1.0	9
28	Advances in whole genome methylomic sequencing. , 2020, , 213-233.		2
29	Data independent acquisition-mass spectrometry (DIA-MS)-based comprehensive profiling of bone metastatic cancers revealed molecular fingerprints to assist clinical classifications for bone metastasis of unknown primary (BMUP). <i>Translational Cancer Research</i> , 2020, 9, 2390-2401.	0.4	3
30	The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review. <i>Frontiers in Oncology</i> , 2020, 10, 533.	1.3	17
31	Development and Clinical Validation of a 90-Gene Expression Assay for Identifying Tumor Tissue Origin. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1139-1150.	1.2	13
32	From bench to bedside: Biosensing strategies to evaluate endocrine disrupting compounds based on epigenetic events and their potential use in medicine. <i>Environmental Toxicology and Pharmacology</i> , 2020, 80, 103450.	2.0	1
33	Exploring the biological hallmarks of cancer of unknown primary: where do we stand today?. <i>British Journal of Cancer</i> , 2020, 122, 1124-1132.	2.9	41
34	"Metastatic Cancer of Unknown Primary" or "Primary Metastatic Cancer"? <i>Frontiers in Oncology</i> , 2019, 9, 1546.	1.3	35
35	Machine learning systems and precision medicine: A conceptual and experimental approach to single individual statistics. , 2020, , 91-119.		0
36	Clinical efficiency of epigenetic drugs therapy in bone malignancies. <i>Bone</i> , 2021, 143, 115605.	1.4	28

#	ARTICLE	IF	CITATIONS
39	Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition. Nature Communications, 2021, 12, 2498.	5.8	20
40	Knowledge bases and software support for variant interpretation in precision oncology. Briefings in Bioinformatics, 2021, 22, .	3.2	9
41	Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?. Cancer Treatment Reviews, 2021, 97, 102204.	3.4	24
42	MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary. Molecular Oncology, 2021, 15, 2732-2751.	2.1	14
43	Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP). Scientific Reports, 2021, 11, 15112.	1.6	2
44	Detection of hypermethylation BRCA1/2 gene promoter in breast tumours among Moroccan women. Molecular Biology Reports, 2021, 48, 7147-7152.	1.0	1
45	Great future or greedy venture: Precision medicine needs philosophy. Health Science Reports, 2021, 4, e376.	0.6	1
46	Occult triple negative male breast cancer. The usefulness of molecular platforms. A case report. Current Problems in Cancer Case Reports, 2021, 4, 100097.	0.1	1
47	Novel immunotherapeutic approaches to cancer: Voltage-gated sodium channel expression in immune cells and tumors. , 2022, , 83-109.		4
48	Photonic crystal barcode: An emerging tool for cancer diagnosis. Smart Materials in Medicine, 2021, 2, 182-195.	3.7	5
49	Maternal Prenatal Exposures in Pregnancy and Autism Spectrum Disorder: An Insight into the Epigenetics of Drugs and Diet as Key Environmental Influences. Advances in Neurobiology, 2020, 24, 143-162.	1.3	10
50	Causes, effects, and clinical implications of perturbed patterns within the cancer epigenome. Seminars in Cancer Biology, 2022, 83, 15-35.	4.3	11
52	Insights from the genetic and transcriptional characterization of a cancer of unknown primary ( CUP) Tj ETQq0 0 0 ggBT /Overlock 10 Tf	3.3	4
53	CÃ¡ncer metastÃ¡sico con primario desconocido. Una revisiÃ³n. Revista Colombiana De GastroenterologÃ­a, 2018, 33, 134.	0.1	4
54	90-Gene Expression Profiling for Tissue Origin Diagnosis of Cancer of Unknown Primary. Frontiers in Oncology, 2021, 11, 722808.	1.3	5
55	Artificial intelligence: A new era of technological advancement in oncology care. International Journal of Molecular and Immuno Oncology, 0, 4, 56-57.	0.0	1
56	Pan-cancer methylome analysis for cancer diagnosis and classification of cancer cell of origin. Cancer Gene Therapy, 2022, 29, 428-436.	2.2	12
57	Non-Epithelial Ovarian Cancers: How Much Do We Really Know?. International Journal of Environmental Research and Public Health, 2022, 19, 1106.	1.2	46

#	ARTICLE	IF	CITATIONS
58	Precision medicine with multi-omics strategies, deep phenotyping, and predictive analysis. Progress in Molecular Biology and Translational Science, 2022, , 101-125.	0.9	11
59	Case Report: Molecular Profiling Assists in the Diagnosis and Treatment of Cancer of Unknown Primary. Frontiers in Oncology, 2022, 12, 723140.	1.3	1
60	Multi-omics strategies for personalized and predictive medicine: past, current, and future translational opportunities. Emerging Topics in Life Sciences, 2022, 6, 215-225.	1.1	10
61	SEOM-GETTHI clinical guideline for the practical management of molecular platforms (2021). Clinical and Translational Oncology, 2022, 24, 693-702.	1.2	1
62	Algal Polysaccharides-Based Nanoparticles for Targeted Drug Delivery Applications. Starch/Staerke, 0, , 2200014.	1.1	11
63	CancerNet: a unified deep learning network for pan-cancer diagnostics. BMC Bioinformatics, 2022, 23, .	1.2	5
64	Case Report: Successful Immunotherapy Improved the Prognosis of the Unfavorable Subset of Cancer of Unknown Primary. Frontiers in Immunology, 0, 13, .	2.2	2
65	Global Consensus on the Initial Diagnostic Workup of Cancer of Unknown Primary. SSRN Electronic Journal, 0, , .	0.4	1
66	PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors. American Journal of Surgical Pathology, 2022, 46, 1467-1476.	2.1	32
67	Emergent impact of lifestyle on tumor progression and response to therapy. International Review of Cell and Molecular Biology, 2022, , ix-xvii.	1.6	0
68	Magnetic resonance imaging and 18F-fludeoxyglucose positron emission tomography/computed tomography findings of retroperitoneal clear cell carcinoma with an unknown primary site: A case report. Frontiers in Medicine, 0, 9, .	1.2	2
69	Cervical squamous cell carcinoma of unknown primary: Oncological outcomes and prognostic factors. Frontiers in Oncology, 0, 12, .	1.3	2
70	International consensus on the initial diagnostic workup of cancer of unknown primary. Critical Reviews in Oncology/Hematology, 2023, 181, 103868.	2.0	8
71	RASSF1A inhibits epithelial-to-mesenchymal transition of gastric cancer cells by downregulating p-JNK. Cell Biology International, 0, , .	1.4	0
72	Cancer epigenetics in clinical practice. Ca-A Cancer Journal for Clinicians, 2023, 73, 376-424.	157.7	43
73	Clinical features of cancer with unknown primary site (clinical features, treatment, prognosis of) Tj ETQq1 1 0.784314 rgBT /Qverlock	1.1	4
74	Circulating Tumor DNA Methylation Biomarkers for Characterization and Determination of the Cancer Origin in Malignant Liver Tumors. Cancers, 2023, 15, 859.	1.7	6
75	From Biology to Diagnosis and Treatment: The Ariadne's Thread in Cancer of Unknown Primary. International Journal of Molecular Sciences, 2023, 24, 5588.	1.8	3

#	ARTICLE	IF	CITATIONS
76	Cancer of unknown primary site in the mandibular region: A case report. <i>Oncology Letters</i> , 2023, 25, .	0.8	0
77	Risk factors for cancer of unknown primary: a literature review. <i>BMC Cancer</i> , 2023, 23, .	1.1	0
79	Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0